Positive Results For Ramucirumab as Single Agent in Phase III Gastric Cancer Trial

Eli Lilly announced that the REGARD trial, a Phase III study of ramucirumab (IMC-1121B) in patients with metastatic gastric cancer, met its primary endpoint of improved overall survival and also showed prolonged progression-free survival. This trial is the first Phase III data read-out for ramucirumab.